United Therapeutics Corporation (UTHR)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,539,000 | 1,274,300 | 950,600 | 593,900 | 638,900 |
| Revenue | US$ in thousands | 2,877,400 | 2,327,500 | 1,936,300 | 1,685,500 | 1,483,300 |
| Pretax margin | 53.49% | 54.75% | 49.09% | 35.24% | 43.07% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $1,539,000K ÷ $2,877,400K
= 53.49%
United Therapeutics Corporation's pretax margin has shown a positive trend over the period from December 31, 2020, to December 31, 2024, increasing from 43.07% to 53.49%. This indicates the company's ability to generate profits before accounting for taxes on its revenues has been improving steadily. The upward trend in pretax margin reflects efficient cost management, higher revenue generation, or a combination of both. This improvement signifies that the company has been able to control its operating expenses and generate higher income relative to its total revenue. Overall, the growth in pretax margin suggests stronger operational efficiency and profitability for United Therapeutics Corporation over the analyzed period.
Peer comparison
Dec 31, 2024